News - BioPharm International

ADVERTISEMENT

News

Biotec Services Doubles Temperature-Controlled Processing Capacity

August 14, 2014

UK-based Biotec Services International is increasing temperature-controlled facility capacity.

ISPE Hits Recruitment Milestone for Quality Metrics Pilot Program

August 11, 2014

ISPE announced that its Quality Metrics Pilot Program has 12 companies and 32 sites participating

Cubist Pharmaceuticals Recalls CUBICIN

August 8, 2014

Cubist Pharmaceuticals voluntarily recalls certain lots of CUBICIN 500 mg in 10 mL single-use vials because of the presence of particulate matter.

New Blockbuster Drugs Will More than Triple Acute Coronary Syndrome Treatment Market Value by 2023

August 5, 2014

GlobalData's report looks at the growth of monoclonal antibodies in the market for acute coronary syndrome treatment.

Allied Minds and Bristol-Myers Squibb Advance Innovation in US Academia

August 5, 2014

Allied-Bristol Life Sciences will focus on converting university research into therapeutic candidates.

EMA Invites Comments on New Guidance for Vaccine Development

August 4, 2014

EMA has released the second module of a new guideline on influenza vaccines for a six-month public consultation. The guidance covers the non-clinical and clinical requirements for the development of new influenza vaccines and aims to facilitate the prompt assessment of new vaccines. It follows the publication of a module on the quality requirements.

Pfizer to Acquire Vaccines from Baxter

July 30, 2014

Pfizer announced an agreement to acquire Baxter International?s marketed vaccines for $635 million.

GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate

July 29, 2014

The regulatory filing marks the first step in the approval process toward making RTS,S available as an addition to existing tools currently recommended for malaria prevention.

Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies

July 28, 2014

Bristol-Myers Squibb and Ono Pharmaceutical will jointly develop and commercialize immuno-oncology drugs for Japan, South Korea, and Taiwan.

ADVERTISEMENT

ADVERTISEMENT

Click here